Early gene expression changes by Epstein-Barr virus infection of B-cells indicate CDKs and survivin as therapeutic targets for post-transplant lymphoproliferative diseases

International Journal of Cancer

Volumn 133, Issue 10, 2013, Pages 2341-2350

  Bernasconi, Michele ^a   Ueda, Seigo ^a   Krukowski, Patricia ^a   Bornhauser, Beat C ^a   Ladell, Kristin ^a   Dorner, Marcus ^a   Sigrist, Juerg A ^a   Campidelli, Cristina ^b   Aslandogmus, Roberta ^a   Alessi, Davide ^a   Berger, Christoph ^a   Pileri, Stefano A ^b   Speck, Roberto F ^c   Nadal, David ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Epstein Barr virus (EBV); post transplant lymphoproliferative disorder (PTLD); survivin

Indexed keywords

CYCLIN B1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 1; FLAVOPIRIDOL; SEPANTRONIUM BROMIDE; SURVIVIN; TERAMEPROCOL;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL CYCLE; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; EPSTEIN BARR VIRUS INFECTION; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPATHOGENESIS; LYMPHOBLASTOID CELL LINE; LYMPHOCYTE PROLIFERATION; NONHUMAN; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; TONSIL CELL; UPREGULATION; VIRUS CELL INTERACTION;

EPSTEIN-BARR VIRUS (EBV); POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER (PTLD); SURVIVIN;

APOPTOSIS; B-LYMPHOCYTES; CDC2 PROTEIN KINASE; CELL CYCLE; CYCLIN B1; EPSTEIN-BARR VIRUS INFECTIONS; GENE EXPRESSION; HERPESVIRUS 4, HUMAN; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LEUKOCYTES, MONONUCLEAR; LYMPHOPROLIFERATIVE DISORDERS; ORGAN TRANSPLANTATION; TRANSFORMATION, GENETIC; UP-REGULATION;

EID: 84883816724     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28239     Document Type: Article

References (48)

1. Gross TG, Savoldo B, Punnett A,. Posttransplant lymphoproliferative diseases. Pediatr Clin North Am 2010; 57: 481-503.
2. Cohen JM, Cooper N, Chakrabarti S, et al. EBV-related disease following haematopoietic stem cell transplantation with reduced intensity conditioning. Leuk Lymphoma 2007; 48: 256-69.
3. Shaffer DR, Rooney CM, Gottschalk S,. Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation. Immunotherapy 2010; 2: 663-71.
4. Hatton O, Martinez OM, Esquivel CO,. Emerging therapeutic strategies for Epstein-Barr virus+ post-transplant lymphoproliferative disorder. Pediatr Transplant 2012; 16: 220-9.
5. Thorley-Lawson DA,. Epstein-Barr-Virus: exploiting the immune system. Nat Rev Immunol 2001; 1: 75-82.
6. Olagne J, Caillard S, Gaub MP, et al. Post-transplant lymphoproliferative disorders: determination of donor/recipient origin in a large cohort of kidney recipients. Am J Transplant 2011; 11: 1260-9.
7. Rickinson A, Kieff E,. Epstein-Barr virus. In:, Knipe DM, Howley PM, eds. Fields virology, vol. 2. Philadelphia: Lippincott Williams & Wilkins Publishers, 2001. 2575-627.
8. Speck SH, Ganem D,. Viral latency and its regulation: lessons from the gamma-herpesviruses. Cell Host Microbe 2010; 8: 100-15.
9. Doubrovina E, Oflaz-Sozmen B, Prockop SE, et al. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation. Blood 2012; 119: 2644-56.
10. Kamdar KY, Rooney CM, Heslop HE,. Posttransplant lymphoproliferative disease following liver transplantation. Curr Opin Organ Transplant 2011; 16: 274-80.
11. Dorner M, Zucol F, Berger C, et al. Distinct ex vivo susceptibility of B-cell subsets to Epstein-Barr virus infection according to differentiation status and tissue origin. J Virol 2008; 82: 4400-12.
12. Ladell K, Dorner M, Zauner L, et al. Immune activation suppresses initiation of lytic Epstein-Barr virus infection. Cell Microbiol 2007; 9: 2055-69.
13. Crouch J, Leitenberg D, Smith BR, et al. Epstein-Barr virus suspension cell assay using in situ hybridization and flow cytometry. Cytometry 1997; 29: 50-7.
14. Türker C, Akal F, Joho D, et al. B-fabric: an open source life sciences data management system. In:, Winslett M, ed. Scientific and statistical database management, vol. 5566. Berlin/Heidelberg: Springer, 2009. 185-90.
15. Turker C, Akal F, Schlapbach R,. Life sciences data and application integration with B-fabric. J Integr Bioinform 2011; 8: 159.
16. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4: 249-64.
17. Dai M, Wang P, Boyd AD, et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 2005; 33: e175.
18. Nikitin PA, Yan CM, Forte E, et al. An ATM/Chk2-mediated DNA damage-responsive signaling pathway suppresses Epstein-Barr virus transformation of primary human B cells. Cell Host Microbe 2010; 8: 510-22.
19. Lin TS, Ruppert AS, Johnson AJ, et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 2009; 27: 6012-18.
20. Bennet N,. Oral CDK4/6 inhibitor in clinical trials. Lancet Oncol 2012; 13: e91.
21. Gregory CD, Dive C, Henderson S, et al. Activation of Epstein-Barr virus latent genes protects human B cells from death by apoptosis. Nature 1991; 349: 612-14.
22. Ambrosini G, Adida C, Altieri DC,. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-21.
23. Goga A, Yang D, Tward AD, et al. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat Med 2007; 13: 820-7.
24. O'Connor DS, Grossman D, Plescia J, et al. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci USA 2000; 97: 13103-7.
25. Ryan BM, O'Donovan N, Duffy MJ,. Survivin: a new target for anti-cancer therapy. Cancer Treat Rev 2009; 35: 553-62.
26. Ng SB, Selvarajan V, Huang G, et al. Activated oncogenic pathways and therapeutic targets in extranodal nasal-type NK/T cell lymphoma revealed by gene expression profiling. J Pathol 2011; 223: 496-510.
27. Carter KL, Cahir-McFarland E, Kieff E,. Epstein-barr virus-induced changes in B-lymphocyte gene expression. J Virol 2002; 76: 10427-36.
28. Lee JE, Nam HY, Shim SM, et al. Expression phenotype changes of EBV-transformed lymphoblastoid cell lines during long-term subculture and its clinical significance. Cell Prolif 2010; 43: 378-84.
29. Dai Y, Tang Y, He F, et al. Screening and functional analysis of differentially expressed genes in EBV-transformed lymphoblasts. Virol J 2012; 9: 77.
30. Price AM, Tourigny JP, Forte E, et al. Analysis of Epstein-Barr virus-regulated host gene expression changes through primary B-cell outgrowth reveals delayed kinetics of latent membrane protein 1-mediated NF-kappaB activation. J Virol 2012; 86: 11096-106.
31. Chen A, Zhao B, Kieff E, et al. EBNA-3B- and EBNA-3C-regulated cellular genes in Epstein-Barr virus-immortalized lymphoblastoid cell lines. J Virol 2006; 80: 10139-50.
32. White RE, Groves IJ, Turro E, et al. Extensive co-operation between the Epstein-Barr virus EBNA3 proteins in the manipulation of host gene expression and epigenetic chromatin modification. PLoS One 2010; 5: e13979.
33. Gregorovic G, Bosshard R, Karstegl CE, et al. Cellular gene expression that correlates with EBER expression in Epstein-Barr Virus-infected lymphoblastoid cell lines. J Virol 2011; 85: 3535-45.
34. Lu J, Murakami M, Verma SC, et al. Epstein-Barr Virus nuclear antigen 1 (EBNA1) confers resistance to apoptosis in EBV-positive B-lymphoma cells through up-regulation of survivin. Virology 2011; 410: 64-75.
35. O', Neil JD, Owen TJ, Wood VH, et al. Epstein-Barr virus-encoded EBNA1 modulates the AP-1 transcription factor pathway in nasopharyngeal carcinoma cells and enhances angiogenesis in vitro. J Gen Virol 2008; 89: 2833-42.
36. Spender LC, Cornish GH, Sullivan A, et al. Expression of transcription factor AML-2 (RUNX3, CBF(alpha)-3) is induced by Epstein-Barr virus EBNA-2 and correlates with the B-cell activation phenotype. J Virol 2002; 76: 4919-27.
37. Maier S, Staffler G, Hartmann A, et al. Cellular target genes of Epstein-Barr virus nuclear antigen 2. J Virol 2006; 80: 9761-71.
38. Schlee M, Holzel M, Bernard S, et al. C-myc activation impairs the NF-kappaB and the interferon response: implications for the pathogenesis of Burkitt's lymphoma. Int J Cancer 2007; 120: 1387-95.
39. Lucchesi W, Brady G, Dittrich-Breiholz O, et al. Differential gene regulation by Epstein-Barr virus type 1 and type 2 EBNA2. J Virol 2008; 82: 7456-66.
40. Canaan A, Haviv I, Urban AE, et al. EBNA1 regulates cellular gene expression by binding cellular promoters. Proc Natl Acad Sci USA 2009; 106: 22421-6.
41. Spender LC, Cannell EJ, Hollyoake M, et al. Control of cell cycle entry and apoptosis in B lymphocytes infected by Epstein-Barr virus. J Virol 1999; 73: 4678-88.
42. Chao SH, Price DH,. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem 2001; 276: 31793-9.
43. Palermo RD, Webb HM, West MJ,. RNA polymerase II stalling promotes nucleosome occlusion and pTEFb recruitment to drive immortalization by Epstein-Barr virus. PLoS Pathog 2011; 7: e1002334.
44. Hino R, Uozaki H, Inoue Y, et al. Survival advantage of EBV-associated gastric carcinoma: survivin up-regulation by viral latent membrane protein 2A. Cancer Res 2008; 68: 1427-35.
45. Tracey L, Perez-Rosado A, Artiga MJ, et al. Expression of the NF-kappaB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively. J Pathol 2005; 206: 123-34.
46. Cohen M, De Matteo E, Narbaitz M, et al. Epstein-Barr virus presence in pediatric diffuse large B-cell lymphoma reveals a particular association and latency patterns: analysis of viral role in tumor microenvironment. Int J Cancer 2013; 132: 1572-1580.
47. Castillo JJ, Beltran BE, Miranda RN, et al. Epstein-barr virus-positive diffuse large B-cell lymphoma of the elderly: what we know so far. Oncologist 2011; 16: 87-96.
48. Cheson BD, Bartlett NL, Vose JM, et al. A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma. Cancer 2012; 118: 3128-34.